FDA Approves RSV Drug for Children Up to 24 Months
July 17th 2023AstraZeneca's new drug, a monoclonal antibody, was given FDA approval after the Antimicrobial Drugs Advisory Committee (AMDAC) to the FDA voted in June to recommend the approval of nirsevimab (Beyfortus) for the prevention of respiratory syncytial virus (RSV) disease in infants.
OIG's Adverse Events Toolkits: Preventing Patient Harm
July 17th 2023As an oversight agency for the Department of Health and Human Services, the Office of Inspector General is responsible for ensuring the safety and effectiveness of Medicare and Medicaid programs, with a huge priority being patient care. These toolkits provide additional guidance on how to avoid patient injury.
Opinion: Post Pandemic Strategies Are Inadequate To Assure Public Safety
July 13th 2023In his analysis, Kevin Kavanagh, MD, explores the measures taken by the infectious disease sector in response to the pandemic, pointing out both effective and ineffective approaches. He also discusses how the pandemic has affected the treatment of other infectious diseases.
Candida auris: Using Public Health Messaging to Address Prevention
March 31st 2023Despite the recent CDC warning and frightening media coverage, understanding which patients are at a higher risk of Candida auris is important too. The lead author of the recent CDC's study spoke to ICT's sister brand for further insights on the threat.